Treatments for chronic myeloid leukemia: a qualitative systematic review
Roxanne Ferdinand,1 Stephen A Mitchell,2 Sarah Batson,2 Indra Tumur11Pfizer, Tadworth, UK; 2Abacus International, Bicester, UKBackground: Chronic myeloid leukemia (CML) is a myeloproliferative disorder of blood stem cells. The tyrosine kinase inhibitor (TKI) imatinib was the first targeted therapy l...
Main Authors: | Ferdin, R, Mitchell SA, Batson S, Tumur I |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2012-08-01
|
Series: | Journal of Blood Medicine |
Online Access: | http://www.dovepress.com/treatments-for-chronic-myeloid-leukemia-a-qualitative-systematic-revie-a10614 |
Similar Items
-
Systematic review of dasatinib in chronic myeloid leukemia
by: Breccia M, et al.
Published: (2013-03-01) -
Advances in the treatment of chronic myeloid leukemia
by: Morley Kimberly, et al.
Published: (2011-08-01) -
TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
by: Michele Baccarani, et al.
Published: (2014-01-01) -
Dasatinib in chronic myeloid leukemia: a review
by: Dolly G Aguilera, et al.
Published: (2009-03-01) -
Optimized Treatment Schedules for Chronic Myeloid Leukemia.
by: Qie He, et al.
Published: (2016-10-01)